Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CART Cells for Relapsed/Refractory B-cell Lymphoma
NCT03146533Phase 2Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- May 2017
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B cell lymphoma, sponsored by Shenzhen Second People's Hospital. Primary endpoints: Safety as assessed by the occurrence of study related adverse events at 6 months, Maximum Tolerated Dose at 2 months and 4 more. Status: unknown.
02
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03146533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146533.